EHS
EHS

Anika Therapeutics receives FDA 510(k) clearance for injectable bone substitute



Anika Therapeutics Inc. has announced FDA 510(k) clearance for Tactoset, an injectable bone substitute designed to augment suture anchor fixation, according to a company press release.
Tactoset is a calcium phosphate-based bone graft substitute that features a hyaluronic acid (HA) core for easy injection, according to the release.
“Poor quality bone and suture anchor pullout is a real problem for patients in our industry, and surgeons can now use Tactoset to augment their suture anchor fixation and reinforce it from inside the bone. We’ve taken our proprietary HA-enhanced Tactoset

Source link

EHS
Back to top button